Jump to content

TilehurstResearch

Member
  • Posts

    209
  • Joined

  • Last visited

Everything posted by TilehurstResearch

  1. TilehurstResearch

    FYI

    In reply to: apache123 on Tuesday 15/02/05 07:04am A gold star for you Apache. You went for "an announcement" in yesterday's post. Another step forward for SBP. Seems the market wants a miracle !! Remember, as per the announcement, these patients were on their death beds. Wait till Coramsine is used in the early stages of Cancer. That's what it's all about!!
  2. In reply to: TilehurstResearch on Tuesday 15/02/05 05:42am Just a note on the previous chart. In the last 30 days: Gold up 0.9% in USD and down 2.9% in AUD terms. Helps explain the lack of price movement in the Oz gold stocks. Still, I'd expect some activity today as gold is close to breaking out of trading range top of USD$426 - next resistance at USD$430, then it's on for young and old.
  3. In reply to: remlif on Friday 11/02/05 07:13am Hi remlif. I've just done an intra day and 30 day chart for myself. If you go to: QUOTE NEW! Live currency charts and charts comparing $USD gold to all major currencies. Scroll down to experience our newest live currency exchange format you can produce charts up to 10 years of data. Just check in the RH top corner and you have the option of gold price or currencies. Also, look at the Kitco Index which is a basket of currencies in differing %'s tracking them against the gold price ii USD. This is an excellent chart and tells you if gold price is just USD driven, or is rising stronger than the USD is falling against these currrencies.
  4. TilehurstResearch

    FYI

    In reply to: apache123 on Monday 14/02/05 10:23am apache; more likely to be a new group of investors coming on board. With each positive announcement [ we've just had 2 ] the less the risk factor. So SBP qualifies as a BUY to a broader range of investors. This buying is overdue and was anticipated. I expect it to continue this week and the shares to form a new base price - at what level I could only hazard a guess.......18c/28c??? The buying earlier today was by Brokers not listing their buy orders. I'm sure Steve Carter has had more than 1 Broker phoning him in the last few days. All in all - an encouraging day for the true Solbecians.
  5. QUOTE Prime Minister John Howard expressed his best wishes for the surprise April 8 marriage of the Prince of Wales and Camilla Parker Bowles. She isn't, you know, surely they couldn't be having a..... but then why so soon. ooooh !
  6. TilehurstResearch

    FYI

    Good to find the media showing some interest yesterday. Extensive coverage on some radio stations [94.5FM & 6IX that I heard] plus page 3 of "The West Australian" [our only daily paper]. Didn't see the TV news last night, so don't know if any coverage there, but gist of radio commentary was that further trials would be taking place in Perth following SBP's new drug causing remission and immunity to asbestosis (mesothelioama). 6IX had about a 30 sec news segment. All good stuff SBP.
  7. Gold up in USD but down in AUD
  8. Looks like a time to sit back and wait for gold to find a support level Dipped just below $410 USD before kicking back $2. That's 2 nights in a row it's flirted with the $410 support. Next support at $400 USD. Gold Companies changing tact - see commentary below. Gold Falls for 8th Session in Nine as Miners Trim Hedge Deals Feb. 9 (Bloomberg) -- Gold prices in New York fell for the eighth time in nine sessions on concern that mining companies that sold gold in forward contracts will buy back less of the precious metal for delivery. So-called de-hedging reached a record 14.3 million ounces last year, London-based researcher GFMS Ltd. said in a report today. Repurchases may slow this year because producers have 10 million ounces for deliveries, GFMS said. Gold climbed in the past three years, reaching a 16-year high of $458.70 an ounce on Dec. 2, partly as producers reduced transactions that locked in prices. Miners ``closed a lot of hedges, and there's only a finite amount of hedges,'' said Tom Boustead, an analyst at Refco LLC in New York. ``It's certainly not favorable to the price of gold.'' Gold futures for April delivery fell $1.70, or 0.4 percent, to $412.60 at 10:03 a.m. on the Comex division of the New York Mercantile Exchange. Prices have declined 3.7 percent since Jan. 27. A futures contract is an obligation to buy or sell a commodity at a set price for delivery by a specific date. Some producers increased forward sales when the metal touched a 20-year low in 1999 amid speculation that prices would fall further. AngloGold Ashanti AngloGold Ashanti Ltd., the world's second-largest gold producer, accounted for 2.2 million ounces of de-hedging in the fourth-quarter, GFMS said. The Johannesburg-based miner inherited 5.8 million ounces of hedged metal when it bought Ashanti Goldfields Ltd. Barrick Gold Corp., the world's third-largest producer, reduced its hedge book by 1.85 million ounces in the first nine months of the year. Placer Dome Inc., Canada's second-largest gold producer, reduced its committed metals sales by 1.03 million ounces during the same period to 9.4 million ounces. Producers haven't bought back as much gold in the past six weeks, said John Levin, head of marketing at Mitsui Global Precious Metals, a unit of Mitsui & Co. in New York. ``One of the big supports of the market has diminished by a reasonable amount,'' Levin said. Gold also fell on concern that the International Monetary Fund, which owns 2.1 percent of the world's bullion, may sell some of its precious-metal reserves to reduce poor countries' debt. The Group of Seven industrial nations on Feb. 5 asked the IMF to study ways to trim the debt, including revaluing or selling part of fund's 3,217 metric tons of gold. ``There's still a bit of nervousness over the possibility of the IMF selling its gold reserves,'' Boustead said. The IMF will issue a report at the next G-7 finance meeting, scheduled for April in Washington.
  9. TilehurstResearch

    FYI

    In reply to: The_Muns on Wednesday 09/02/05 05:25pm Hi The-Muns. [moderator] I feel no need to defend my position nor any inclination to respond to such a post by bojangles [new member - think he used to be on another forum - on thin ice]. Encouraging to see in last SBP announcement, the inclusion of layman terms to explain the pharmaceutical language used. Helps with understanding what's being said.
  10. TilehurstResearch

    FYI

    Today's announcement on the psoriasis trials reads well. Next stage will be the key one i.e how effective bla bla. We've already seen the effectiveness in previous publications from SBP so no reason to expect any surprises - should just be a Trial based confirmation of the success they have already had with psoriasis. Remember the pictures of the guy's legs before and after treatment they published some months ago ? TR
  11. TilehurstResearch

    FYI

    Friend copied me on this article. From Aegis by the looks of it. Looks like an up-to-date analysis by them. Quite a good read, again nothing new, but well presented. .............................................................................................................................. Solbec Pharmaceuticals Limited (SBP) Printable Summary Aegis View Consensus Profile Blue Book Financials & Ratios Aegis Archive ASX Announcements Dividends Charts Ethical For more information on what a Blue Book is, please click here. Sector Industry Group Sub Industry Disease Target Life Sciences Biotechnology Biopharmaceuticals Cancer, Psoriasis Company Overview SBP is an Australian based, internationally focused drug development company committed to develop and commercialize better therapies for life threatening and debilitating diseases. SBP's primary focus is on the treatment of cancer, in particular melanoma and malignant mesothelioma. We are also focused on the treatment of the inflammatory skin disorder psoriasis. These projects are based on our platform glycoalkaloid technology, which has proven to be an effective anti tumour agent and to have potential anti-inflammatory activity. Research supports a unique and previously unknown mode of action for the drug. Strategy SBP's management team has considerable international pharmaceutical and scientific experience. Our board has extensive experience in management of public companies. The Glycoalkaloid technology provides a strong platform for launching many, diversified projects and is backed by a solid intellectual property base. The core technology for cancer is held in the parent company, while all new projects are placed into SBP's wholly owned subsidiaries. Subsidiaries hold 100% of the rights to commercialise the various technologies. SBP's expertise is in taking early stage technology and value adding through pre-clinical and early clinical development. Our commercialization strategy is to develop an intellectual property portfolio that includes early clinical data and to licence this to partners in the international biotechnology and pharmaceutical industry for full commercialisation. Key Executives Anthony Kiernan, Non-Executive Chairman : A solicitor with considerable experience in listed public companies. He is also a chairman of Anglicare (WA). Stephen Carter (FAIM, MAICD, MRACI, C.Chem), Managing Director/Chief Executive Officer: An experienced senior manager of mature pharmaceutical and of growth companies, he has dealt successfully with the TGA, the US FDA and other regulatory authorities. He has had wide experience in leading the successful growth of research driven companies. Michael Grant (B.P.E.), Non-Executive Director: Has sixteen years experience in the securities industry in the UK, USA and Australian markets. His financial experience is backed by an early background in medical sciences. Professor John Papadimitriou (AM, OStJ, BA, MB BS, MD, PhD, FRCPath, FRCPA, FIBiol), Non-Executive Director: Emeritus Professor in the School of Surgery and Pathology at the University of Western Australia with an international reputation in both diagnostic and experimental pathology. Director of the Neurological Research Institute and of the Child Health Research Foundation of Western Australia and Deputy of the Australian Research Centre for Medical Engineering. David T Hung (M.D.), Non-Executive Director: President and CEO of Californian drug development company, Medivation Inc. Has specialist medical experience in internal medicine and oncology. He later held senior development roles with Chiron Corp. and served as founding President of Pro.Duct Health Inc. Key investment information Market Cap: $22.7M Capital Structure (M) Ord shares on issue: 168.4 Options (fully diluted): 159.7* Convertible notes/other: n/a * includes 11 million unlisted options. n/a Price as at 08-Feb: $0.14 12 month H/L: $0.11 - $0.24 Market turnover (pa): $21.7M Official listing date: Jun-01 Substantial Shareholders Yandal Investments 5.3% Cash Position Cash (as at Dec-04): $2.8M Years with planned expenditure: 0.9 R&D as % expenditure: 75% Company contact Stephen Carter Managing Director stephen.carter@solbec.com.au 61 8 9446 7555 www.solbec.com.au Main Company R&D Projects - Major Technology & Market 1: SBP002 Cancer Target Market: Cancer $5B pa Coramsine™ exhibits strong anticancer activity in specific cancer cell lines in animals and humans, but is relatively non-toxic to normal cells. This profile is more favourable than most traditional chemotherapeutics. SBP has completed 2 of 3 Phase I/IIA trials conducted to establish safety and dosing parameters. The third is under way. Despite low doses and advanced disease, therapeutic responses have been seen in some early patients. A recent preclinical study of Coramsine™ combination therapy gained national media coverage after curing murine mesothelioma and apparently inducing immunity to the disease. Stage: Phase I/IIA Target Date: Finish 1Q 2005 2: SBP002 Psoriasis Target Market: Psoriasis $3B pa Coramsine™ modulates production of the cytokine Interleukin-6 (IL-6). This has been implicated in inflammatory diseases, such as psoriasis, and other illnesses such as Alzheimer’s disease and arteriosclerosis. SBP has lodged patents to cover IL-6 activity. A Phase I/II study of Coramsine™ in healthy people and chronic psoriasis patients is about to end. Stage: Phase I/IIA Target Date: Finish 1Q 2005 3: Cancer Diagnostics Target Market: Cancer Diagnostics SBP's Coramsine™ patents cover various diagnostic applications and specific test opportunities have been identified. Preliminary studies have shown promising results. We are looking for a strategic co-development partner. Stage: Development Target Date: Mid 2005 4: Skin Cancer in Animals Target Market: Veterinary Coramsine™ is active against a number of skin cancers in animals. Preliminary studies have shown good activity against squamous cell and basal cell carcinoma as well as melanoma in cats, dogs and horses. SBP is currently in discussion with potential co-development partners. Stage: Pre-Clinical Studies Target Date: Mid 2005 Aegis Equities Comments Market Position: SBP is commercialising Coramsine™ (SBP002), derived from the weed Devil's Apple, which has shown promising preclinical anti-cancer trial results. SBP’s strategy is to gain a fast-track FDA approval by initially tackling cancers with very poor outlooks, like mesothelioma. Coramsine™ also induces a positive immune response while sparing lymph cells from the damage typical of anti-cancer treatments. SBP002 appears to be topically active against psoriasis, a large, poorly served market. SBP farms its own supply of Devil's Apple. Milestone Record: During the Dec-04 quarter, SBP’s lead compound Coramsine™ completed the second stage of the phase I trial for psoriasis, again showing no unwanted side-effects of application to normal skin. The final stage involves observing how well psoriasis responds to treatment and whether any side-effects are caused. A small study of Coramsine™ plus an immune enhancing agent in mice confirmed the drug’s ability to kill mesothelioma cells. SBP also appointed IDT Ausralia to manufacture compound for planned phase II trials and secured access to a potential complementary agent to Coramsine™ from Hybridon. Risk Profile: SBP's risk profile is dominated by its dependence on Coramsine™ for success, so risk will decline with each clinical trial success. Patent risk will decrease as grants are made in different jurisdictions. The company had cash levels of $2.8M at Dec-04, so it is likely to need to raise money over the next 12 - 18 months. Coramsine™ Clinical Trial Materials Share price performance Source: Bloomberg
  12. TilehurstResearch

    FYI

    Happily added another 100k SBPOA today at 12:17pm. The FPO's dropped .5c after normal trading closed, during settlement period - 4:05pm. While the timing of events remains out of our hands, it's the events that I am backing: -2nd lot of PH1/11a trials results -Psoriasis trial results + what happens next with this part of Coramsine development -new mouse pre-clinical trials to test combination therapy [say July] -commencement of PH11 trials -announcement out of left field on anything e.g. major Pharma Co in USA........ What would be a huge bonus would be if the ASX allowed SBP to move the expiry dates of the options out by 6 months to cover the unexpected extra time they needed as a result of immune system being stimulated by Coramsine and warranting immediate investigation. Unlikely, but hey, stranger things have happened and as some of the above events will be prior to Sept 2005, probably not necessary. easy life - keep smoking TR
  13. TilehurstResearch

    FYI

    Looking to the future of SBP: An opinion from TilehurstResearch • Funding. The conversion of the options is where the additional capital requirements were always planned to come from; not a new issue to raise capital. Hence the tranced exercise prices as the development of the science progressed, adding value to the underlying SP. • Given the unexpected breakthrough from the initial trials [mice and men] SBP would have been remiss to ignore the affect SBP002 [as it was then] had on the immune system. This has the potential to make SBP an absolute fortune. • Hence the 2nd PH1/11a trials. • And now, as per this week’s announcement, further studies on an immune stimulating formulation – to be completed by end of June 2005, on the immunological characteristics from the inclusion of a 3rd party [Hybridon Inc] immune response product, CpG. • Back to Funding. The above immune response breakthrough obviously warranted SBP to extend the trials and undertake further pre-clinical trials to better understand this trigger. Fortunately they have world class credentialed scientists onboard now to work in collaboration with the University of WA team, using best practice to obtain and evaluate the information. • This is not a time delay through any shortcomings by SBP. Rather, a commonsense approach to produce the best product for PH2 trials, FDA approval, and IND and ODS status approvals. • I expect a further PH1/11a trial may have to be carried out with the resultant enhanced Coramsine. This being the case, the $64mill dollar question is: will these pre clinical trials and progress in new PH1/11a be advanced enough by the 2005 option conversion price [20c] date in September? • I believe the timing will be tight. But let’s not forget that the information released to the market at the conclusion of the pre-clinical trials at the end of June, the psoriasis trial results, the other collaborations with major Pharma Companies overseas [as eluded to in Steve Carter’s email of 1st Feb] all have the potential individually or collectively to have the SP ‘in the money’ by the 3rd week of September. Who has the greatest incentive to achieve this? - SBP !! • So why the sell-off this week? I can only guess that a few, and only a few based on $ value of trades involved, were traders, not investors. Add to that the fact that the market for SBP has been very thin for a couple of months. Their action, as traders, meant they chose to ignore the fact that the options don’t expire until 3rd week September 2006. By that time, a conversion price of 30c will in my opinion be seen as a bargain. But let’s hope that the option price will be ‘in the money’ this September, giving SBP the capital injection it will most likely be getting close to needing for PH2. • Even a 20+ % conversion rate, say about 30mill options @ 20c, would inject $6 million into their coffers. This would still leave just under 120mill options outstanding to be converted at 30c = $36million. Pharmaceutical stocks and gold stocks are like chalk and cheese. The former are trying to create it for us - the latter are trying to find it for us. So trade the gold stocks and invest in the Pharmas.
  14. "IMF + G-7" Gold Commentary from Paul Van Eeeden - copied from www.kitco.com. 4/2/5. Worth a read......................... IMF Gold Sales February 04, 2004 The gold price has been weak of late, down ten dollars in the past seven days. Thursday’s decline was blamed on remarks made by the British Chancellor of the Exchequer, Gordon Brown, about a possible revaluation of the International Monetary Fund’s gold reserves, and the possibility that some of those reserves might be sold to provide debt relief to poor countries. The IMF has about one hundred million ounces of gold which are valued on its books at between $40 and $50 an ounce. To keep the arithmetic simple, let’s say the IMF has one hundred million ounces valued at $40 an ounce. Revaluing that gold at $440 an ounce would instantaneously create $40 billion dollars on the IMF’s balance sheet. The $40 billion dollars so “created†can then be used to offset some of the debt owed to the IMF by poor nations. Such a revaluation and cancellation of debt does not necessarily involve the sale of any gold -- it can be done with accounting entries. Another possibility is that the IMF actually sells some, or all of its gold, and uses the proceeds to assist poor countries with their debt. If the IMF sold its gold it could, for instance, buy a basket of sovereign debt and use the interest earned on the portfolio for debt relief. This option could potentially be more detrimental to the gold market. We are talking about a lot of gold: the IMF has 103.4 million ounces, or 3,216 tonnes. If all that gold were dumped on the market at once it could have a negative impact on the gold price. However, it is highly unlikely that the IMF would do that. It is far more likely that the IMF will use off-market transactions to assist poor countries with high debt burdens, as it did with Brazil and Mexico a few years ago when these countries’ debt payments to the IMF were coming due. Between December 1999 and April 2000 the IMF “sold†12.9 million ounces of gold to Brazil and Mexico at prevailing market prices and the profit on the sales (market price for gold less approximately $40 an ounce) was placed in special accounts designated for debt relief. Brazil and Mexico then immediately sold the same gold back to the IMF, at the same price they paid for it, to settle their debt payments that were coming due. The net effect was that the IMF still had exactly the same amount of gold on its books. It’s not clear from the IMF’s website how, exactly, Mexico and Brazil’s overall debts were impacted. I assume that their debts were just re-financed in the process, although some of the money created on the IMF’s balance sheet by this revaluation of its gold reserves could have been used to offset the total amount of outstanding debt as well. It is clear, however, that the money created from the revaluation of the IMF’s gold is being used to provide debt relief to poor, and heavily indebted countries. Such off-market transactions are similar to a pure revaluation of the IMF’s gold and do not involve any gold actually being sold on the market. Since many of the same poor countries that the IMF is trying to help are actually gold producers, and since in many cases these countries’ gold exports account for a large (sometimes very large) percentage of their foreign currency receipts, off-market transactions are far more palatable than actual gold sales. If we assume that some of the IMF’s gold will hit the market, then we have to consider what impact that will have. For instance, if the IMF sells its gold over a period of five to ten years, the net impact on the gold price should be negligible. In a previous commentary (“Central Bank sales and the gold priceâ€ÂÂÂÂÂÂ, December 5, 2003) I showed that Central Bank gold sales did not affect the gold price during the period from 1990 to 2003. During that time Central Banks sold roughly 5,500 tonnes of gold -- far more than the IMF has to sell -- and since that did not negatively impact the gold market, I have no reason to believe that IMF gold sales will negatively impact the market either. The only impact that Central Bank sales did have on the gold market during the 1990s was that they caused speculative selling on the date of the announcement. But the announcements were all made in arrears and the gold price always recovered within a few weeks of the announcements. In other words, the actual Central Bank sales, themselves, did not affect the market. That is also exactly what we saw on Thursday: a comment by the British Chancellor of the Exchequer caused a speculative sell-off in gold -- without an ounce of IMF gold being sold. I expect the gold price will recover within a few weeks, unless something else, like a rally in the US dollar, occurs. Another thing to keep in mind is that the G7 is split over how to deal with the debt of poor countries. To revalue or sell the IMF’s gold will require an 85 percent majority vote. The United States alone has a 17 percent vote, and could therefore block the IMF from selling its gold. Given that the IMF needs an 85 percent majority to sell its gold, that actual gold sales would hurt the same countries (gold producers) the IMF is trying to help, and that more benign off-market transactions are also a way to help those countries, I doubt that we are going to see massive IMF gold liquidations in the near future. What we are likely to see is a replay of the 1990s when Central Bank gold sales were attracting a lot of attention and were blamed for the decline in the gold price while, in fact, the gold price was merely mirroring the US dollar. With the dollar now declining the gold price (in US dollars) will continue its upward trend and nervousness about IMF gold sales is likely to cause counter-trend corrections, which should turn out to be good buying opportunities. So I am not worried about this week’s decline in the gold price. Paul van Eeden
  15. TilehurstResearch

    FYI

    In reply to: IVY on Thursday 03/02/05 03:12pm I.V. The words in SC's email to me, that I have copied verbatum, regarding the 2nd PH1 trial are SC's words. Could I suggest you contact SC yourself if you feel you have been misled ? I personally have no further issues with SBP or SC. easy life.....
  16. TilehurstResearch

    FYI

    In reply to: lyndon_webster on Thursday 03/02/05 07:11am Hi Lyndon, Apache and Tickles. The announcement just out will answer some more questions. Lyndon - glad I'm not the only one tyhat was unaware of 2nd Phase 1 trial. I can't answer your quesions and I'm sure SC will reply when he can. All looking good now. Could I really have undermined the SP ? Maybe so - Steve Carter felt I had. I guess this confirms the status of Sharescene as the top Market forum, as if we didn't know already. Go SBP......go hard in 2005.
  17. TilehurstResearch

    FYI

    In reply to: TilehurstResearch on Wednesday 02/02/05 08:10am The following response from Steve Carter is "the other agenda". An update and full overview of Solbec's current status direct from the CEO and M.D., Steve Carter. While my methods are sometimes crude, rude and unattractive, I have the answer I wanted. Now I can share it with you. [i have highlighted one point that I was not aware of - the 2nd Phase 1 study]. From : Stephen Carter <stephen.carter@solbec.com.au> Sent : Tuesday, 1 February 2005 12:25:41 PM Drug development is a complex, time consuming and expensive process. This being said lets look at the facts regarding Solbec; • Solbec has Identified the active components in BEC • Solbec began the process of developing BEC for Skin Cancers • during the early studies it was noted that the purified drug(SBP002) was active against a number of cancers and decided to focus on internal cancers • We have carried out full pre clinical studies to confirm the activity, safety, toxicology etc in animals • In Dec 2003 we began Phase I studies in advanced cancer patients. • In June last year the board announced that this study was successful and we would progress the clinical development • We reported safety and preliminary efficacy in this trial (That is we reported a successful trial and preliminary results) • In June 2004 we began a second Phase 1 study to gain further information This is almost complete • In October 2004 we began Phase I/II studies in Psoriasis. • WE are currently producing product for a more advanced clinical program. • These studies are going well and are ahead of Schedule (Not delays and slippages as you refer to) • Solbec is working on an immune stimulating formulation and has reported good results from this work. • Solbec have developed a horticultural facility and grow approx 6000 plants for extraction of the drug. • Solbec have built a manufacturing facility for extraction and purification of the drug • Solbec have a number of strong collaborations in place with internationally recognized groups • Solbec are in discussions with a number of the world’s largest Pharma companies re our products. • Solbec has boosted the medical/scientific capacity of the board with Prof Papadimitriou and Dr. Hung. • Solbec have worked on increasing the liquidity of the stock (thereby potentially increasing the price) by applying for an ADR listing and Listing in Berlin which opens up investors in US and Europe as potential shareholders Solbec is definitely not procrastinating and in fact has carried out significantly more work in a much shorter time frame than a majority of its competitors, with very promising results. This work has been done economically with the shareholders best interests first and foremost in our minds. Solbec is a great company with great products and a dedicated and experienced team. We are focused on achieving our goals and increasing the value of your investment. I look forward to your continuing support. If you wish to discuss this please call me. Regards Steve Stephen Carter Managing Director and Chief Executive Officer Solbec Pharmaceuticals Ltd. Unit 1 298 Selby Street Osborne Park. 6017 Western Australia PO Box 2142 Churchlands 6018 Western Australia. Phone +61(08)94467555 Facsimile +61(08)94468777 Mobile 0412154029 email sjcarter@solbec.com.au
  18. TilehurstResearch

    FYI

    QUOTE I hear what most of you are saying, however, I do have another agenda that hopefully I will be able to divulge in the fullness of time. Time this morning prevents me from posting the result of my "other agenda". But let me say, I have been rightfully chastised by Stephen Carter and I'll take that on the chin. An apology to the Board [esp SC] will go out at the same time. SBP are alive and well and I will post [hopefuly by 6pm WST] the summary of where SBP are at as of yesterday, verbatum from Steve Carter. I'm currently working !! He has provided me with an excellent overview and summary. None of the information is new to the public but the way it is presented should satisfy any other shareholders that had become frustrated with the lack of information in the last couple of months. TR
  19. mme and others. Check out their top 10 shareholders. These are the well credentialed names you want to see taking a position in an emerging gold stock. When gold heads north again, it's the stocks like DEG who will give the best rewards. Top management; close to infrastructure [gas pipeline and great Northern Highway run through Turner River lease] - excellent blue sky potential from very active drilling program, already underway, that keeps coming up with additional resources. Still plenty of targets to be drilled yet. DYOR. Happy to hold, and will add should there be any short term weakness in gold price.
  20. TilehurstResearch

    FYI

    "The message he is sending to the market is that the options may well be out-of-the-money come September." Quote from my first post on this issue. Glad to see some old/new names coming out of the woodwork on SBP. A public forum achieves more than visiting Tony Kiernan 'in house'. They are only 4-5km away from where I live and I am no stranger there. SC is who I meet with when required. IVY. Would I be correct in thinking your username is phoenetic for I.V. ? [not related to this issue but just struck me the other night. Clever if it is; and your medical knowledge sort of supports it......lol ]. I hear what most of you are saying, however, I do have another agenda that hopefully I will be able to divulge in the fullness of time. Based on the phone calls I received yesterday, there is lots of hair flying around at SBP and other locations. FIRST OBJECTIVE ACHIEVED BY USING SS. I'll say no more on this issue until it has played itself out. avagoodweekend TR
  21. TilehurstResearch

    FYI

    In reply to: IVY on Thursday 27/01/05 09:33pm Ivy, I always appreciate what you have to say. 1] Correct, it wasn't the AGM but it was a meeting held while SC was in the States. 2] Why a 'token' amount? If you look at the market for SBPOA, he did very well to sell 400k ! And at what price ? 3] Will we see more "changes in Directors' holdings" ?? - namely by this individual ? 4] An EGM would be a last resort. 5] Watch this space.
  22. TilehurstResearch

    FYI

    The following email has just been sent to sjcarter@solbec.com.au "Good [or not so good] morning Steve. The following issue is gathering momentum very fast. Strongly suggest SBP take the necessary action i.e. get Michael Grant's resignation, before shareholders call an Extraordinary General Meeting. 14 so far [in 1 hour of phoning around] support my stance. To the CEO and M.D. of Solbec Pharmaceuticals: - Anthony Kiernan and Stephen Carter Following is my post on sharescene.com on Thursday 27th January, 2005. I have also spoken to some key investors and they are as angry as I am with Michael Grant's action. "What Michael Grant has done is what I have suggested more than once on SS. Last Setember, about 10% of options were converted at 12c. So the converters were giving away the value of their options and paying 12c/FPO share when they could have sold their options on market and bought the shares [about 1:4 as Michael Grunt-mispelling on purpose!] with the proceeds + any further cash they had to obtain a larger gty. You can still do this and get 1 FPO for about 4 options. It's a matter of watching the market and seling the options with a price differential to the FPO's of about 12c+. My issue is: A Director is not acting ethically if he does this. I don't care how many FPO's or options he has - as a Director he is looking after himself, not the shareholders! His performance at the last AGM was pathetic in SC's absence. I will be contacting SBP after discussing this with 3 other LARGE shareholders demanding Michael Grant's resignation. The message he is sending to the market is that the options may well be out-of-the-money come September. NOT HAPPY MICHAEL. "
  23. TilehurstResearch

    FYI

    Further to my post at 7:02pm, please feel free to email me with the name you hold your shares/options in and, if possible the quantities. This information will be kept confidential and only used to give SBP the message. The large shareholders will be phone dby me tonight. TR
  24. TilehurstResearch

    FYI

    What Michael Grant has done is what I have suggested more than once on SS. Last Setember, about 10% of options were converted at 12c. So the converters were giving away the value of their options and paying 12c/FPO share when they could have sold their options on market and bought the shares [about 1:4 as Michael Grunt-mispelling on purpose!] with the proceeds + any further cash they had to obtain a larger gty. You can still do this and get 1 FPO for about 4 options. It's a matter of watching the market and seling the options with a price differential to the FPO's of about 12c+. My issue is: A Director is not acting ethically if he does this. I don't care how many FPO's or options he has - as a Director he is looking after himself, not the shareholders! His performance at the last AGM was pathetic in SC's absence. I will be contacting SBP after discussing this with 3 other LARGE shareholders demanding Michael Grant's resignation. The message he is sending to the market is that the options may well be out-of-the-money come September. NOT HAPPY MICHAEL.
  25. Nice figures in qtrly report. Word is that DEG will be focusing even more on Au and the platinum play MAY be sold off to the JV partner. Will take a month or 2 to get a resource estimate for Mt Berghaus but has potential to be 10 fold the 203k oz at Wingina Well. Has strike length 10 times that of Wingina ! Now it's up to the G-7 summit to sink the US$. DEG is my gold stock for 2005/2006. Stick with this one over the medium term - it has the potential to be something special.
×
×
  • Create New...